Clinical Trial

Trial Protocol ID USOR 23251_D9722C00001_ EvoPAR-Breast01 *STAR*

Trial Description

A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)(D9722C00001)

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsors

  • AstraZeneca
  • Fortrea Inc.